Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


04.10.2021

3 Anticancer Res
3 BJU Int
2 BMC Urol
1 Br J Cancer
1 Cancer Imaging
1 Clin Cancer Res
2 Clin Imaging
4 Eur Urol
1 J Natl Cancer Inst
2 J Urol
1 Lancet Oncol
1 Oncogene
1 Oncol Rep
5 PLoS One
1 Proc Natl Acad Sci U S A
2 Prostate
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Anticancer Res

  1. KOPELKE S, Bartscht T, Schild SE, Tvilsted S, et al
    Frequency and Risk Factors of Sleep Disturbances in Patients With Prostate Cancer Assigned to Local or Loco-regional Radiotherapy.
    Anticancer Res. 2021;41:5165-5169.
    PubMed         Abstract available

  2. TAKAI M, Kawakami K, Fujita Y, Kato T, et al
    Kartogenin Inhibits Prostate Cancer Cell Growth Through Smad2 Activation and Decreases Androgen Receptor Nuclear Localization.
    Anticancer Res. 2021;41:4753-4759.
    PubMed         Abstract available

  3. FUJIMOTO N, Harada K, Shiota M, Tomisaki I, et al
    Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Anticancer Res. 2021;41:4687-4695.
    PubMed         Abstract available


    BJU Int

  4. GULDBAEK MV, Fode M, Jensen CFS, Sonksen J, et al
    'Case of the Month' from Herlev and Gentofte Hospital, Denmark: metastatic prostate cancer in a man with late-onset hypogonadism following testosterone-replacement therapy.
    BJU Int. 2021;128:428-430.
    PubMed        

  5. MONTORSI F, Stabile A, Gandaglia G, Fossati N, et al
    Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
    BJU Int. 2021;128:523.
    PubMed        

  6. MARRA G, Calleris G, Marquis A, Oderda M, et al
    Reply to letter by Montorsi et al. Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
    BJU Int. 2021;128:524.
    PubMed        


    BMC Urol

  7. ASHIDA S, Yamasaki I, Kawada C, Fukuhara H, et al
    Evaluation of a rapid one-step PSA test for primary prostate cancer screening.
    BMC Urol. 2021;21:135.
    PubMed         Abstract available

  8. GARCIA-FLORES M, Sanchez-Lopez CM, Ramirez-Calvo M, Fernandez-Serra A, et al
    Isolation and characterization of urine microvesicles from prostate cancer patients: different approaches, different visions.
    BMC Urol. 2021;21:137.
    PubMed         Abstract available


    Br J Cancer

  9. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed         Abstract available


    Cancer Imaging

  10. XING P, Chen L, Yang Q, Song T, et al
    Differentiating prostate cancer from benign prostatic hyperplasia using whole-lesion histogram and texture analysis of diffusion- and T2-weighted imaging.
    Cancer Imaging. 2021;21:54.
    PubMed         Abstract available


    Clin Cancer Res

  11. ZHANG H, Orme JJ, Abraha F, Stish BJ, et al
    Phase II evaluation of Stereotactic Ablative Radiotherapy (SABR) and immunity in (11)C-Choline-PET/CT-identified oligometastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-2510.
    PubMed         Abstract available


    Clin Imaging

  12. PATEL N, Coakley FV, Foster BR
    Performance of transgluteal CT-guided biopsy of prostate lesions in men without rectal access: A retrospective study.
    Clin Imaging. 2021;79:225-229.
    PubMed         Abstract available

  13. RAZEK AAKA, El-Diasty T, Elhendy A, Fahmy D, et al
    Prostate Imaging Reporting and Data System (PI-RADS): What the radiologists need to know?
    Clin Imaging. 2021;79:183-200.
    PubMed         Abstract available


    Eur Urol

  14. STAVRINIDES V, Syer T, Hu Y, Giganti F, et al
    False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naive Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.
    Eur Urol. 2021;79:20-29.
    PubMed         Abstract available

  15. DELL'OGLIO P, Meershoek P, Maurer T, Wit EMK, et al
    A DROP-IN Gamma Probe for Robot-assisted Radioguided Surgery of Lymph Nodes During Radical Prostatectomy.
    Eur Urol. 2021;79:124-132.
    PubMed         Abstract available

  16. TRELLES CR, Martinez-Pineiro L
    Re: The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry.
    Eur Urol. 2021 Sep 24. pii: S0302-2838(21)02000.
    PubMed        

  17. REN S, Yang B, Wang D
    Re: Vicenc Ruiz de Porras, Xieng C. Wang, Luis Palomero, et al. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Eur Urol 2021;79:722-33.
    Eur Urol. 2021 Sep 25. pii: S0302-2838(21)02018.
    PubMed        


    J Natl Cancer Inst

  18. MITCHELL AP, Mishra A, Panageas KS, Lipitz-Snyderman A, et al
    Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    J Natl Cancer Inst. 2021 Oct 1. pii: 6379715. doi: 10.1093.
    PubMed         Abstract available


    J Urol

  19. URKMEZ A, Demirel C, Altok M, Bathala TK, et al
    Freehand versus Grid-Based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications.
    J Urol. 2021;206:894-902.
    PubMed         Abstract available

  20. BHAT KRS, Covas Moschovas M, Sandri M, Dell'Oglio P, et al
    A Predictive Preoperative and Postoperative Nomogram for Postoperative Potency Recovery after Robot-Assisted Radical Prostatectomy.
    J Urol. 2021;206:942-951.
    PubMed         Abstract available


    Lancet Oncol

  21. HINDIE E
    Predicting outcomes after (177)Lu-PSMA therapy in castration-resistant prostate cancer.
    Lancet Oncol. 2021;22:e425.
    PubMed        


    Oncogene

  22. LABANCA E, Bizzotto J, Sanchis P, Anselmino N, et al
    Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel.
    Oncogene. 2021 Sep 28. pii: 10.1038/s41388-021-02008.
    PubMed         Abstract available


    Oncol Rep

  23. SHENG W, Xu W, Ding J, Li L, et al
    Curcumol inhibits the malignant progression of prostate cancer and regulates the PDK1/AKT/mTOR pathway by targeting miR9.
    Oncol Rep. 2021;46.
    PubMed         Abstract available


    PLoS One

  24. KOGA F, Ito M, Kataoka M, Fukushima H, et al
    Novel anatomical apical dissection utilizing puboprostatic "open-collar" technique: Impact on apical surgical margin and early continence recovery.
    PLoS One. 2021;16:e0249991.
    PubMed         Abstract available

  25. VETRICHELVAN O, Gorjala P, Goodman O Jr, Mitra R, et al
    Bergamottin a CYP3A inhibitor found in grapefruit juice inhibits prostate cancer cell growth by downregulating androgen receptor signaling and promoting G0/G1 cell cycle block and apoptosis.
    PLoS One. 2021;16:e0257984.
    PubMed         Abstract available

  26. HASHIMOTO Y, Shiina M, Maekawa S, Kato T, et al
    Suppressor effect of catechol-O-methyltransferase gene in prostate cancer.
    PLoS One. 2021;16:e0253877.
    PubMed         Abstract available

  27. MINAMITANI M, Mukai T, Yamashita H, Katano A, et al
    Effects on annual income changes after radical radiotherapy versus after prostatectomy in patients with localized prostate cancer with a specific employment status: A web-based pilot study.
    PLoS One. 2021;16:e0258116.
    PubMed         Abstract available

  28. TSUZUKI S, Nakanishi S, Tamaki M, Oshiro T, et al
    Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
    PLoS One. 2021;16:e0258160.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  29. BELLO T, Paindelli C, Diaz-Gomez LA, Melchiorri A, et al
    Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available


    Prostate

  30. YIN Y, Liu Q, Shao Y, He X, et al
    Regulatory mechanism of androgen receptor on NCAPD3 gene expression in prostate cancer.
    Prostate. 2021 Sep 30. doi: 10.1002/pros.24245.
    PubMed         Abstract available

  31. YU C, Niu L, Li L, Li T, et al
    Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Prostate. 2021 Sep 30. doi: 10.1002/pros.24229.
    PubMed         Abstract available


    Urology

  32. ESDAILLE AR, Ibilibor C, Ii AH, Palmer NR, et al
    Access and Representation: A Narrative Review of the Disparities in Access to Clinical Trials and Precision Oncology in Black men with Prostate Cancer.
    Urology. 2021 Sep 25. pii: S0090-4295(21)00893.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: